Lysis

Syncromune, Inc. Announces FDA Clearance of IND Application for SYNC-T SV-102, a First-In-Class Combination Multi-Target Immunotherapy for Metastatic Castrate-Resistant Prostate Cancer

Retrieved on: 
금요일, 5월 31, 2024
Patient, CRS, API, Food, Immune system, FDA, AACR, IND, Neoplasm, PRS, Prostate cancer, Freezing, Lysis, Pharmaceutical industry

FORT LAUDERDALE, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T, an in situ personalized therapy platform optimized for solid tumor cancers, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for SYNC-T SV-102, its lead candidate for the treatment of patients with metastatic castrate-resistant prostate cancer.

Key Points: 
  • "Receiving clearance of our IND is a significant milestone for Syncromune and will allow us to rapidly advance the clinical development of SYNC-T SV-102," said Syncromune’s President and CEO, Eamonn Hobbs.
  • "This clearance, following our recent presentation at AACR of data demonstrating unprecedented response rates, underscores the potential of SYNC-T SV-102 to change the landscape of prostate cancer treatment."
  • "The prospects of this new combination multi-target approach and its broad potential applicability in the treatment of metastatic solid tumor cancers is incredibly exciting."
  • The combination approach is designed to promote T cell activation and proliferation, empowering the immune system to recognize and attack patient-specific cancer throughout the body.

Transgene - First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administered Intravenously, in Non-Small Cell Lung Cancer

Retrieved on: 
수요일, 5월 10, 2023
Biotechnology, Health, Oncology, Clinical Trials, IL-12, AACR, IV, Cancer, American Association for Cancer Research, Toxicity, NSCLC, Lung cancer, Doctor of Philosophy, Euronext Paris, Lysis, MD, Patient, Toxicology, International Cancer Genome Consortium, Safety, Pharmaceutical industry, Vaccine

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that the first patient has been dosed in Delivir, a Phase I clinical trial evaluating TG6050.

Key Points: 
  • Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that the first patient has been dosed in Delivir, a Phase I clinical trial evaluating TG6050.
  • This multi-mechanism oncolytic immunotherapy is administered intravenously in patients with recurrent metastatic advanced non-small cell lung cancer (NSCLC).
  • The Delivir trial will enroll up to 36 patients with advanced NSCLC who have failed standard therapeutic options, including immune checkpoint inhibitors.
  • Initial data were presented at the American Association for Cancer Research (AACR) Annual Meeting, April 14 -19, 2023 and can be accessed here .

Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration

Retrieved on: 
금요일, 1월 6, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Cancer, ICIS, Euronext Paris, International Cancer Genome Consortium, ANSM, Neoplasm, Patient, Tumor microenvironment, CTA, Disseminated disease, Medication, Lysis, Large-cell lung carcinoma, IL-12, IV, National Agency for Food and Drug Administration and Control, Safety, NSCLC, Pharmaceutical industry, Vaccine

It has been engineered to express human IL-12, a cytokine that triggers a powerful antitumor immune response, and a full length anti-CTLA4 antibody.

Key Points: 
  • It has been engineered to express human IL-12, a cytokine that triggers a powerful antitumor immune response, and a full length anti-CTLA4 antibody.
  • TG6050 has been designed to be administered intravenously, a route of administration that has been demonstrated to be safe and feasible with an Invir.IO™ based OV.
  • Intratumoral injection, where the drug is injected directly into the tumor, is currently the only approved route of administration for an oncolytic virus.
  • Intravenous administration addresses a broader range of patients with solid tumors who are not suitable for intratumoral administration.

Shoreline Biome Issued Patent for Cell Lysis and Preparation of High Molecular Weight DNA from Modified Cells

Retrieved on: 
화요일, 11월 2, 2021
Science, Method, Research, Entrepreneurship, PCR, Eukaryote, Disease, Goal, Atomic mass, High-molecular-weight kininogen, CRISPR, Patent, United States Patent and Trademark Office, Software, Lysis, Bacteria, Cell, Health, DNA, Antibiotics

FARMINGTON, Conn., Nov. 2, 2021 /PRNewswire-PRWeb/ -- Shoreline Biome , a microbiome research company that develops tools for characterizing microbiome populations down to the strain level, was recently awarded a new patent by the United States Patent and Trademark Office for "Methods for Cell Lysis and Preparation of High Molecular Weight DNA from Modified Cells."

Key Points: 
  • FARMINGTON, Conn., Nov. 2, 2021 /PRNewswire-PRWeb/ -- Shoreline Biome , a microbiome research company that develops tools for characterizing microbiome populations down to the strain level, was recently awarded a new patent by the United States Patent and Trademark Office for "Methods for Cell Lysis and Preparation of High Molecular Weight DNA from Modified Cells."
  • The patent outlines the method and materials for the lysis of modified eukaryotic cells.
  • This method, which is used in the Shoreline Biome Rapid Prep Kits, provides researchers with a set of reagents to quickly and inexpensively generate high molecular weight single-stranded DNA ideal for the generation of long PCR fragments.
  • The process is ideal for screening modified cells by a technique such as CRISPR to identify cells that have been successfully modified.

The Worldwide Cell Lysis/Cell Fractionation Industry is Expected to Reach $4.1 Billion by 2026

Retrieved on: 
목요일, 4월 1, 2021
Branches of biology, Biology, Cell biology, Molecular biology, Cell death, Lysis, Protein purification, Protein

The global cell lysis market size is projected to reach USD 4.1 billion by 2026 from USD 2.9 billion in 2021, at a CAGR of 7.2% from 2021 to 2026.

Key Points: 
  • The global cell lysis market size is projected to reach USD 4.1 billion by 2026 from USD 2.9 billion in 2021, at a CAGR of 7.2% from 2021 to 2026.
  • Based on the product, the cell lysis market is segmented into consumables and instruments.
  • Protein purification and isolation segment to register the highest growth in the cell lysis market during the forecast period.
  • The protein purification and isolation segment is projected to witness the highest growth in the cell lysis market during the forecast period.

Cell Lysis/Cell Fractionation Market by Product, Cell Type, Application and End-user - Global Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
화요일, 3월 30, 2021
Health, Biotechnology, Branches of biology, Biology, Molecular biology, Life sciences, Cell biology, Biotechnology, Cell death, Lysis, Protein purification, Protein

The global cell lysis market size is projected to reach USD 4.1 billion by 2026 from USD 2.9 billion in 2021, at a CAGR of 7.2% from 2021 to 2026.

Key Points: 
  • The global cell lysis market size is projected to reach USD 4.1 billion by 2026 from USD 2.9 billion in 2021, at a CAGR of 7.2% from 2021 to 2026.
  • Protein purification and isolation segment to register the highest growth in the cell lysis market during the forecast period.
  • Based on the application, the cell lysis market is segmented into protein purification and isolation, nucleic acid isolation and purification and other application.
  • The protein purification and isolation segment is projected to witness the highest growth in the cell lysis market during the forecast period.

Shoreline Biome Receives Patent for Innovative Bacteria Lysis Method

Retrieved on: 
수요일, 9월 16, 2020
Branches of biology, Bacteriology, Microscopy, Microbiomes, Microbiology, Bacteria, Microbiome, Microbiota, Biome, Lysis

The patent outlines the method and materials for the lysis of bacteria present in microbiomes as well as bacterial cell isolates.

Key Points: 
  • The patent outlines the method and materials for the lysis of bacteria present in microbiomes as well as bacterial cell isolates.
  • This method, used in the Shoreline Biome Rapid Prep Kits and in the front end of the Shoreline Complete kits , provides researchers with a set of reagents to quickly, comprehensively, and uniformly lyse bacteria.
  • Shoreline Biome sells the reagents used in this method in 16-well and 96-well plate format.
  • Shoreline Biome accelerates breakthroughs in microbiome research by developing transformative discovery tools that characterize microbiome populations down to the strain level.

Cell Lysis & Disruption: Global Market Size, Share & Trends (2019-2025) - ResearchAndMarkets.com

Retrieved on: 
목요일, 8월 22, 2019
Biotechnology, Health, Other Science, Science, Cell biology, Lysis, Disruption, Cell disruption, Cell, Biotechnology

The "Cell Lysis & Disruption Market Size, Share & Trends Analysis Report By Cell Type, By Product, By Technique (Physical Disruption, Reagent-based), By Application, By End Use, By Region, And Segment Forecasts, 2019 - 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell Lysis & Disruption Market Size, Share & Trends Analysis Report By Cell Type, By Product, By Technique (Physical Disruption, Reagent-based), By Application, By End Use, By Region, And Segment Forecasts, 2019 - 2025" report has been added to ResearchAndMarkets.com's offering.
  • Demand for cell lysis & disruption is driven by the immense growth of the biotechnology sector globally.
  • Technological developments in procedures involved to release cellular organelles have paved the way for higher adoption of cell disruption methods.
  • As retrieval and purification of biopharmaceuticals involve cell disruption, a rise in demand for biopharma would lead to the subsequent growth of the market.

Cell Lysis & Disruption Market Size Worth $5.65 Billion by 2025: Grand View Research, Inc.

Retrieved on: 
수요일, 7월 24, 2019
Cell biology, Lysis, Cell disruption, Disruption

SAN FRANCISCO, July 24, 2019 /PRNewswire/ -- The global cell lysis & disruption market size is expected to reach USD 5.65 billion by 2025 registering a CAGR of 8.31%, according to a new report by Grand View Research, Inc. Demand for cell lysis & disruption is driven by the immense growth of the biotechnology sector globally.

Key Points: 
  • SAN FRANCISCO, July 24, 2019 /PRNewswire/ -- The global cell lysis & disruption market size is expected to reach USD 5.65 billion by 2025 registering a CAGR of 8.31%, according to a new report by Grand View Research, Inc. Demand for cell lysis & disruption is driven by the immense growth of the biotechnology sector globally.
  • This is majorly due to the high adoption of biotech processes in the pharmaceutical, agricultural, and bio-services industries.
  • As retrieval and purification of biopharmaceuticals involve cell disruption, a rise in demand for biopharma would lead to the subsequent growth of the market.
  • Grand View Research has segmented the global cell lysis & disruption market on the basis of technique, product, cell type, application, end use, and region:
    Cell Lysis & Disruption Technique Outlook (Revenue, USD Million, 2014 - 2025)

Cell Lysis & Disruption Market Size Worth $5.65 Billion by 2025: Grand View Research, Inc.

Retrieved on: 
수요일, 7월 24, 2019
Cell biology, Lysis, Cell disruption, Disruption

SAN FRANCISCO, July 24, 2019 /PRNewswire/ -- The global cell lysis & disruption market size is expected to reach USD 5.65 billion by 2025 registering a CAGR of 8.31%, according to a new report by Grand View Research, Inc. Demand for cell lysis & disruption is driven by the immense growth of the biotechnology sector globally.

Key Points: 
  • SAN FRANCISCO, July 24, 2019 /PRNewswire/ -- The global cell lysis & disruption market size is expected to reach USD 5.65 billion by 2025 registering a CAGR of 8.31%, according to a new report by Grand View Research, Inc. Demand for cell lysis & disruption is driven by the immense growth of the biotechnology sector globally.
  • This is majorly due to the high adoption of biotech processes in the pharmaceutical, agricultural, and bio-services industries.
  • As retrieval and purification of biopharmaceuticals involve cell disruption, a rise in demand for biopharma would lead to the subsequent growth of the market.
  • Grand View Research has segmented the global cell lysis & disruption market on the basis of technique, product, cell type, application, end use, and region:
    Cell Lysis & Disruption Technique Outlook (Revenue, USD Million, 2014 - 2025)